ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Metabolic Disorders Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-25R2545
Home | Market Reports | Health| Pharmacy| Drugs & Medications
COVID 19 Impact on Metabolic Disorders Drugs Market Global Research Reports 2020 2021
BUY CHAPTERS

Metabolic Disorders Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-25R2545
Report
September 2024
Pages:121
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
Kowa
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma

Metabolic Disorders Drugs - Market Size

The global market for Metabolic Disorders Drugs was estimated to be worth US$ 82150 million in 2023 and is forecast to a readjusted size of US$ 160970 million by 2030 with a CAGR of 10.1% during the forecast period 2024-2030

Metabolic Disorders Drugs - Market

Metabolic Disorders Drugs - Market

Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Metabolic Disorders Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Metabolic Disorders Drugs by region & country, by Type, and by Application.
The Metabolic Disorders Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorders Drugs.
Market Segmentation

Scope of Metabolic Disorders Drugs - Market Report

Report Metric Details
Report Name Metabolic Disorders Drugs - Market
Forecasted market size in 2030 US$ 160970 million
CAGR 10.1%
Forecasted years 2024 - 2030
Segment by Type:
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Metabolic Disorders Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Metabolic Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Metabolic Disorders Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Metabolic Disorders Drugs - Market size in 2030?

Ans: The Metabolic Disorders Drugs - Market size in 2030 will be US$ 160970 million.

Who are the main players in the Metabolic Disorders Drugs - Market report?

Ans: The main players in the Metabolic Disorders Drugs - Market are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma

What are the Application segmentation covered in the Metabolic Disorders Drugs - Market report?

Ans: The Applications covered in the Metabolic Disorders Drugs - Market report are Hospital, Retail Pharmacy

What are the Type segmentation covered in the Metabolic Disorders Drugs - Market report?

Ans: The Types covered in the Metabolic Disorders Drugs - Market report are Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug, Other

Recommended Reports

Metabolic Disorder Drugs

Hormone & Genetic Drugs

Mental & Growth Disorders

1 Market Overview
1.1 Metabolic Disorders Drugs Product Introduction
1.2 Global Metabolic Disorders Drugs Market Size Forecast
1.2.1 Global Metabolic Disorders Drugs Sales Value (2019-2030)
1.2.2 Global Metabolic Disorders Drugs Sales Volume (2019-2030)
1.2.3 Global Metabolic Disorders Drugs Sales Price (2019-2030)
1.3 Metabolic Disorders Drugs Market Trends & Drivers
1.3.1 Metabolic Disorders Drugs Industry Trends
1.3.2 Metabolic Disorders Drugs Market Drivers & Opportunity
1.3.3 Metabolic Disorders Drugs Market Challenges
1.3.4 Metabolic Disorders Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Metabolic Disorders Drugs Players Revenue Ranking (2023)
2.2 Global Metabolic Disorders Drugs Revenue by Company (2019-2024)
2.3 Global Metabolic Disorders Drugs Players Sales Volume Ranking (2023)
2.4 Global Metabolic Disorders Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Metabolic Disorders Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Metabolic Disorders Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Metabolic Disorders Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Metabolic Disorders Drugs
2.9 Metabolic Disorders Drugs Market Competitive Analysis
2.9.1 Metabolic Disorders Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Metabolic Disorders Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Glycogen Metabolism Disease Drug
3.1.2 Lipid Metabolism Disease Drug
3.1.3 Amino Acid Metabolism Drug
3.1.4 Other
3.2 Global Metabolic Disorders Drugs Sales Value by Type
3.2.1 Global Metabolic Disorders Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Metabolic Disorders Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Metabolic Disorders Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Metabolic Disorders Drugs Sales Volume by Type
3.3.1 Global Metabolic Disorders Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Metabolic Disorders Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Metabolic Disorders Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Metabolic Disorders Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Retail Pharmacy
4.2 Global Metabolic Disorders Drugs Sales Value by Application
4.2.1 Global Metabolic Disorders Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Metabolic Disorders Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Metabolic Disorders Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Metabolic Disorders Drugs Sales Volume by Application
4.3.1 Global Metabolic Disorders Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Metabolic Disorders Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Metabolic Disorders Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Metabolic Disorders Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Metabolic Disorders Drugs Sales Value by Region
5.1.1 Global Metabolic Disorders Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Metabolic Disorders Drugs Sales Value by Region (2019-2024)
5.1.3 Global Metabolic Disorders Drugs Sales Value by Region (2025-2030)
5.1.4 Global Metabolic Disorders Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Metabolic Disorders Drugs Sales Volume by Region
5.2.1 Global Metabolic Disorders Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Metabolic Disorders Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Metabolic Disorders Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Metabolic Disorders Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Metabolic Disorders Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Metabolic Disorders Drugs Sales Value, 2019-2030
5.4.2 North America Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Metabolic Disorders Drugs Sales Value, 2019-2030
5.5.2 Europe Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Metabolic Disorders Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Metabolic Disorders Drugs Sales Value, 2019-2030
5.7.2 South America Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Metabolic Disorders Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Metabolic Disorders Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Metabolic Disorders Drugs Sales Value
6.2.1 Key Countries/Regions Metabolic Disorders Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Metabolic Disorders Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Metabolic Disorders Drugs Sales Value, 2019-2030
6.3.2 United States Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Metabolic Disorders Drugs Sales Value, 2019-2030
6.4.2 Europe Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Metabolic Disorders Drugs Sales Value, 2019-2030
6.5.2 China Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Metabolic Disorders Drugs Sales Value, 2019-2030
6.6.2 Japan Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Metabolic Disorders Drugs Sales Value, 2019-2030
6.7.2 South Korea Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Metabolic Disorders Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Metabolic Disorders Drugs Sales Value, 2019-2030
6.9.2 India Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Metabolic Disorders Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Metabolic Disorders Drugs Product Offerings
7.1.5 Merck Recent Development
7.2 Novartis
7.2.1 Novartis Company Information
7.2.2 Novartis Introduction and Business Overview
7.2.3 Novartis Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Metabolic Disorders Drugs Product Offerings
7.2.5 Novartis Recent Development
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Information
7.3.2 Takeda Pharmaceutical Introduction and Business Overview
7.3.3 Takeda Pharmaceutical Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Takeda Pharmaceutical Metabolic Disorders Drugs Product Offerings
7.3.5 Takeda Pharmaceutical Recent Development
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Information
7.4.2 Astra Zeneca Introduction and Business Overview
7.4.3 Astra Zeneca Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Astra Zeneca Metabolic Disorders Drugs Product Offerings
7.4.5 Astra Zeneca Recent Development
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Information
7.5.2 Boehringer Ingelheim Introduction and Business Overview
7.5.3 Boehringer Ingelheim Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Boehringer Ingelheim Metabolic Disorders Drugs Product Offerings
7.5.5 Boehringer Ingelheim Recent Development
7.6 KOWA
7.6.1 KOWA Company Information
7.6.2 KOWA Introduction and Business Overview
7.6.3 KOWA Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.6.4 KOWA Metabolic Disorders Drugs Product Offerings
7.6.5 KOWA Recent Development
7.7 Kythera
7.7.1 Kythera Company Information
7.7.2 Kythera Introduction and Business Overview
7.7.3 Kythera Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Kythera Metabolic Disorders Drugs Product Offerings
7.7.5 Kythera Recent Development
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Information
7.8.2 Fuji yakuhin Introduction and Business Overview
7.8.3 Fuji yakuhin Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Fuji yakuhin Metabolic Disorders Drugs Product Offerings
7.8.5 Fuji yakuhin Recent Development
7.9 LG Life Science
7.9.1 LG Life Science Company Information
7.9.2 LG Life Science Introduction and Business Overview
7.9.3 LG Life Science Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.9.4 LG Life Science Metabolic Disorders Drugs Product Offerings
7.9.5 LG Life Science Recent Development
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Information
7.10.2 Metsubishi Tanabe Pharma Introduction and Business Overview
7.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Offerings
7.10.5 Metsubishi Tanabe Pharma Recent Development
8 Industry Chain Analysis
8.1 Metabolic Disorders Drugs Industrial Chain
8.2 Metabolic Disorders Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Metabolic Disorders Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Metabolic Disorders Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
Kowa
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
List of Tables
    Table 1. Metabolic Disorders Drugs Market Trends
    Table 2. Metabolic Disorders Drugs Market Drivers & Opportunity
    Table 3. Metabolic Disorders Drugs Market Challenges
    Table 4. Metabolic Disorders Drugs Market Restraints
    Table 5. Global Metabolic Disorders Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Metabolic Disorders Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Global Metabolic Disorders Drugs Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Metabolic Disorders Drugs Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Metabolic Disorders Drugs Price by Company (2019-2024) & (USD/Unit)
    Table 10. Key Manufacturers Metabolic Disorders Drugs Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Metabolic Disorders Drugs Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Metabolic Disorders Drugs
    Table 13. Global Metabolic Disorders Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Drugs as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Metabolic Disorders Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Metabolic Disorders Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Metabolic Disorders Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Metabolic Disorders Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Metabolic Disorders Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Metabolic Disorders Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Metabolic Disorders Drugs Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Metabolic Disorders Drugs Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Metabolic Disorders Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Metabolic Disorders Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Metabolic Disorders Drugs Price by Type (2019-2024) & (USD/Unit)
    Table 27. Global Metabolic Disorders Drugs Price by Type (2025-2030) & (USD/Unit)
    Table 28. Global Metabolic Disorders Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Metabolic Disorders Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Metabolic Disorders Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Metabolic Disorders Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Metabolic Disorders Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Metabolic Disorders Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Metabolic Disorders Drugs Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Metabolic Disorders Drugs Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Metabolic Disorders Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Metabolic Disorders Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Metabolic Disorders Drugs Price by Application (2019-2024) & (USD/Unit)
    Table 39. Global Metabolic Disorders Drugs Price by Application (2025-2030) & (USD/Unit)
    Table 40. Global Metabolic Disorders Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Metabolic Disorders Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Metabolic Disorders Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Metabolic Disorders Drugs Sales Value by Region (2019-2024) & (%)
    Table 44. Global Metabolic Disorders Drugs Sales Value by Region (2025-2030) & (%)
    Table 45. Global Metabolic Disorders Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Metabolic Disorders Drugs Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Metabolic Disorders Drugs Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Metabolic Disorders Drugs Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Metabolic Disorders Drugs Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Metabolic Disorders Drugs Average Price by Region (2019-2024) & (USD/Unit)
    Table 51. Global Metabolic Disorders Drugs Average Price by Region (2025-2030) & (USD/Unit)
    Table 52. Key Countries/Regions Metabolic Disorders Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Metabolic Disorders Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Metabolic Disorders Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Metabolic Disorders Drugs Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Metabolic Disorders Drugs Sales Volume, (2025-2030) & (K Units)
    Table 57. Merck Company Information
    Table 58. Merck Introduction and Business Overview
    Table 59. Merck Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 60. Merck Metabolic Disorders Drugs Product Offerings
    Table 61. Merck Recent Development
    Table 62. Novartis Company Information
    Table 63. Novartis Introduction and Business Overview
    Table 64. Novartis Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 65. Novartis Metabolic Disorders Drugs Product Offerings
    Table 66. Novartis Recent Development
    Table 67. Takeda Pharmaceutical Company Information
    Table 68. Takeda Pharmaceutical Introduction and Business Overview
    Table 69. Takeda Pharmaceutical Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 70. Takeda Pharmaceutical Metabolic Disorders Drugs Product Offerings
    Table 71. Takeda Pharmaceutical Recent Development
    Table 72. Astra Zeneca Company Information
    Table 73. Astra Zeneca Introduction and Business Overview
    Table 74. Astra Zeneca Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 75. Astra Zeneca Metabolic Disorders Drugs Product Offerings
    Table 76. Astra Zeneca Recent Development
    Table 77. Boehringer Ingelheim Company Information
    Table 78. Boehringer Ingelheim Introduction and Business Overview
    Table 79. Boehringer Ingelheim Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 80. Boehringer Ingelheim Metabolic Disorders Drugs Product Offerings
    Table 81. Boehringer Ingelheim Recent Development
    Table 82. KOWA Company Information
    Table 83. KOWA Introduction and Business Overview
    Table 84. KOWA Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 85. KOWA Metabolic Disorders Drugs Product Offerings
    Table 86. KOWA Recent Development
    Table 87. Kythera Company Information
    Table 88. Kythera Introduction and Business Overview
    Table 89. Kythera Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 90. Kythera Metabolic Disorders Drugs Product Offerings
    Table 91. Kythera Recent Development
    Table 92. Fuji yakuhin Company Information
    Table 93. Fuji yakuhin Introduction and Business Overview
    Table 94. Fuji yakuhin Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 95. Fuji yakuhin Metabolic Disorders Drugs Product Offerings
    Table 96. Fuji yakuhin Recent Development
    Table 97. LG Life Science Company Information
    Table 98. LG Life Science Introduction and Business Overview
    Table 99. LG Life Science Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 100. LG Life Science Metabolic Disorders Drugs Product Offerings
    Table 101. LG Life Science Recent Development
    Table 102. Metsubishi Tanabe Pharma Company Information
    Table 103. Metsubishi Tanabe Pharma Introduction and Business Overview
    Table 104. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 105. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Offerings
    Table 106. Metsubishi Tanabe Pharma Recent Development
    Table 107. Key Raw Materials Lists
    Table 108. Raw Materials Key Suppliers Lists
    Table 109. Metabolic Disorders Drugs Downstream Customers
    Table 110. Metabolic Disorders Drugs Distributors List
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Metabolic Disorders Drugs Product Picture
    Figure 2. Global Metabolic Disorders Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Metabolic Disorders Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Metabolic Disorders Drugs Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Metabolic Disorders Drugs Sales Price (2019-2030) & (USD/Unit)
    Figure 6. Metabolic Disorders Drugs Report Years Considered
    Figure 7. Global Metabolic Disorders Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Metabolic Disorders Drugs Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Metabolic Disorders Drugs Revenue in 2023
    Figure 10. Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Glycogen Metabolism Disease Drug Picture
    Figure 12. Lipid Metabolism Disease Drug Picture
    Figure 13. Amino Acid Metabolism Drug Picture
    Figure 14. Other Picture
    Figure 15. Global Metabolic Disorders Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Metabolic Disorders Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 17. Global Metabolic Disorders Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 18. Global Metabolic Disorders Drugs Sales Volume Market Share by Type, 2023 & 2030
    Figure 19. Global Metabolic Disorders Drugs Price by Type (2019-2030) & (USD/Unit)
    Figure 20. Product Picture of Hospital
    Figure 21. Product Picture of Retail Pharmacy
    Figure 22. Global Metabolic Disorders Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Metabolic Disorders Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 24. Global Metabolic Disorders Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 25. Global Metabolic Disorders Drugs Sales Volume Market Share by Application, 2023 & 2030
    Figure 26. Global Metabolic Disorders Drugs Price by Application (2019-2030) & (USD/Unit)
    Figure 27. North America Metabolic Disorders Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. North America Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. Europe Metabolic Disorders Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. Europe Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. Asia Pacific Metabolic Disorders Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 33. South America Metabolic Disorders Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 34. South America Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 35. Middle East & Africa Metabolic Disorders Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 36. Middle East & Africa Metabolic Disorders Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 37. Key Countries/Regions Metabolic Disorders Drugs Sales Value (%), (2019-2030)
    Figure 38. Key Countries/Regions Metabolic Disorders Drugs Sales Volume (%), (2019-2030)
    Figure 39. United States Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 40. United States Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 41. United States Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 42. Europe Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 43. Europe Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 44. Europe Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 45. China Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 46. China Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 47. China Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 48. Japan Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Japan Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 50. Japan Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 51. South Korea Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 52. South Korea Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 53. South Korea Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 54. Southeast Asia Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Southeast Asia Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 56. Southeast Asia Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 57. India Metabolic Disorders Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 58. India Metabolic Disorders Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 59. India Metabolic Disorders Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 60. Metabolic Disorders Drugs Industrial Chain
    Figure 61. Metabolic Disorders Drugs Manufacturing Cost Structure
    Figure 62. Channels of Distribution (Direct Sales, and Distribution)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Drugs for Metabolic Disorders Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Metabolic Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metabolism Drugs Market Research Report 2025
Metabolic Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metabolic Disease Drugs Market Research Report 2025
Global Metabolic Disease Therapeutics Market Research Report 2025
Drugs for Lipid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for Treating Metabolic Disorders Market Research Report 2024
Lipid Metabolism Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lipid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Lipid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Glycogen Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycogen Metabolism Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycogen Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Amino Acid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Glycogen Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Amino Acid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Amino Acid Metabolism Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metabolic Disorder Therapeutics Market Insights Forecast to 2030
Amino Acid Metabolism Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions